This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ensign Acquires Healthcare Center, Buyout Spree Continues
by Sapna Bagaria
The acquisition of Healthcare Center adds to Ensign Group's (ENSG) portfolio of skilled nursing and independent living services.
Why Should You Retain Molina Healthcare in Your Portfolio?
by Zacks Equity Research
On the back of its restructuring initiatives and solid membership, Molina Healthcare (MOH) holds enough potential to reap benefits for investors.
Ensign Group (ENSG) Takes Shareholder-Friendly Initiatives
by Zacks Equity Research
Ensign Group (ENSG) clears a quarterly dividend hike to share more profits with investors.
Tenet Healthcare to Divest Units for Streamlining Operations
by Zacks Equity Research
Tenet Healthcare (THC) to sell its Memphis area units for clearing its debt and focusing on core business.
Tenet Healthcare Soars 117.1% YTD: Will Growth Continue?
by Zacks Equity Research
Tenet Healthcare's (THC) partnerships and acquisitions are likely to continue boosting its revenue base, which in turn, might perk up its share price.
Humana's (HUM) Alliances to Offer Relief to Members With CKD
by Zacks Equity Research
Humana (HUM) collaborates with Monogram Health and Somatus to provide its Humana Medicare Advantage and Commercial members, who are renal patients, with better healthcare in select geographies.
Why Should You Retain Anthem (ANTM) Stock in Your Portfolio?
by Zacks Equity Research
Riding high on a growing top line and higher membership, Anthem (ANTM) holds enough potential to reap benefits for investors.
The Zacks Analyst Blog Highlights: Cross Country Healthcare, Genesis Healthcare, Chuy's, Consulting and Huron Consulting
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cross Country Healthcare, Genesis Healthcare, Chuy's, Consulting and Huron Consulting
5 Top Stocks to Buy on Blockbuster Jobs Data
by Zacks Equity Research
U.S. non-farm payroll data for November shows that job creation hasn't slowed but has shown signs of reacceleration. Here are five stocks from the best-performing sectors.
Ensign Group (ENSG) on Buyout Binge to Boost Capabilities
by Zacks Equity Research
Ensign Group's (ENSG) acquisition spree in Texas and Arizona will enhance its portfolio and better serve the local communities.
Here's Why Should You Hold MEDNAX (MD) in Your Portfolio
by Zacks Equity Research
Riding high on its solid top line as well as strategic buyouts, MEDNAX (MD) holds enough potential to generate returns for investors.
Why Should You Hold Centene (CNC) Stock in Your Portfolio?
by Zacks Equity Research
Acquisitions, rising revenues, growing membership and solid capital position carve out a long-term growth story for Centene (CNC).
Magellan Health's PBM Division Unveils Care Management Plan
by Zacks Equity Research
Magellan Health's (MGLN) pharmacy benefit management division's newly-launched plan is expected to drive value-added healthcare.
Humana, Epione Tie Up to Aid Medicare Advantage Members
by Zacks Equity Research
Humana (HUM) inks deal with Epione Health of Oklahoma to provide better patient care.
Why is HCA Healthcare an Attractive Stock for Your Portfolio?
by Zacks Equity Research
Growing revenues and a strong capital position bode well for HCA Healthcare (HCA).
Why Should You Hold Universal Health in Your Portfolio?
by Zacks Equity Research
Banking on its growing top line and strong segments, Universal Health (UHS) holds potential to reap benefits for investors.
Humana (HUM) to Boost Medicare Advantage Network in Hawaii
by Zacks Equity Research
Humana (HUM) teams up with Hawaii Senior Medical Group to enrich patient experience of Medicare Advantage members in the region.
Humana (HUM) Scales New 52-Week High on Solid Q3 Earnings
by Zacks Equity Research
Humana (HUM) reaches a 52-week high, backed by strong-third-quarter results and Medicare business.
Top Ranked Momentum Stocks to Buy for November 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 12th
Genesis Healthcare's (GEN) Q3 Earnings Beat, Improve Y/Y
by Zacks Equity Research
Genesis Healthcare's (GEN) third-quarter results reflect same store occupancy growth, partly offset by lower revenues.
Genesis Healthcare (GEN) to Post Q3 Earnings: What to Expect
by Zacks Equity Research
Genesis Healthcare's (GEN) third-quarter results are likely to reflect weak revenues, partially offset by same store facility growth and lower expenses.
Genesis Healthcare (GEN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Genesis Healthcare (GEN) closed at $1.28, marking a -0.78% move from the previous day.
Is Genesis Healthcare (GEN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GEN) Outperforming Other Medical Stocks This Year?
Genesis Healthcare (GEN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Genesis Healthcare (GEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Genesis Healthcare (GEN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Genesis Healthcare (GEN) closed at $1.38, marking a +0.01% move from the previous day.